Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Capacity increase in response to customer demand for DNA and viral vector production
April 18, 2017
By: Tim Wright
Editor-in-Chief, Contract Pharma
Cobra Biologics has unveiled plans to expand operations at its sites in the UK and Sweden to meet the increased demand of gene and immunotherapy companies to fast track their portfolios through to in-market supply. Over the next two years Cobra will invest up to approximately $19 million on a phased expansion plan, supporting the company’s R&D expertise in developing rapid and cost effective viral vector and DNA plasmid production platforms. The initial phase, will be in the UK and will extend the company’s viral vector Phase III and commercial manufacturing capabilities to support more customers to rapidly advance their products through clinical trials to in-market supply. The second phase, in Sweden, will double capacity for high quality (HQ) DNA plasmid production and characterization, essential for supporting early clinical phase Adeno-associated virus (AAV) and lentivirus manufacture being used by pioneering CAR T-cell therapy companies targeting acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia. The third phase of investment will see the addition of larger clinical and commercial capabilities for GMP DNA production. In total, it is anticipated these investments will create up to 50 new jobs, in addition to the 135 jobs already created in the UK and Sweden since 2011 and will also benefit the wider supply chain companies that provide Cobra with services and facilities. “For almost 20 years Cobra has been manufacturing DNA and viral vectors for its gene therapy customers and we intend to stay at the forefront of this exciting field,” said Peter Coleman, chief executive officer, Cobra Biologics. “Cobra is committed to investing for both present day needs and for the future at this extraordinary time in the history of gene therapy when so many new and potentially life-changing medicines are in the pipe line. Many of these new products have orphan drug status and as a CDMO, we need to respond with a quick and seamless production route to market.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !